Related references
Note: Only part of the references are listed.Tolerability of Nintedanib (BIBF 1120) in Combination with Docetaxel: A Phase 1 Study in Japanese Patients with Previously Treated Non-Small-Cell Lung Cancer
Isamu Okamoto et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Randomized phase II study of nintedanib in metastatic castration-resistant prostate cancer postdocetaxel
Jean-Pierre Droz et al.
ANTI-CANCER DRUGS (2014)
Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysis
Klaus Mross et al.
BMC CANCER (2014)
Phase I clinical trial of nintedanib plus paclitaxel in early HER-2-negative breast cancer (CNIO-BR-01-2010/GEICAM-2010-10 study)
M. Quintela-Fandino et al.
BRITISH JOURNAL OF CANCER (2014)
Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer
L. Rhoda Molife et al.
FUTURE ONCOLOGY (2014)
A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study
Don S. Dizon et al.
GYNECOLOGIC ONCOLOGY (2014)
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
Martin Reck et al.
LANCET ONCOLOGY (2014)
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Luca Richeldi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor
Paul Mesange et al.
ONCOTARGET (2014)
Antifibrotic and Anti-inflammatory Activity of the Tyrosine Kinase Inhibitor Nintedanib in Experimental Models of Lung Fibrosis
Lutz Wollin et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study
Tim Eisen et al.
INVESTIGATIONAL NEW DRUGS (2013)
Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme
Aida Muhic et al.
JOURNAL OF NEURO-ONCOLOGY (2013)
BIBF 1120 (Nintedanib), a Triple Angiokinase Inhibitor, Induces Hypoxia but not EMT and Blocks Progression of Preclinical Models of Lung and Pancreatic Cancer
Bercin Kutluk Cenik et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Phase II study of BIBF1120 in recurrent glioblastoma multiforme
Ulrik Lassen et al.
CANCER RESEARCH (2012)
A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer
M. Reck et al.
ANNALS OF ONCOLOGY (2011)
Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients
G. Bousquet et al.
BRITISH JOURNAL OF CANCER (2011)
Novel therapeutic approaches for pulmonary fibrosis
Arnab Datta et al.
BRITISH JOURNAL OF PHARMACOLOGY (2011)
Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer
Jonathan A. Ledermann et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Idiopathic pulmonary fibrosis
Talmadge E. King et al.
LANCET (2011)
Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Luca Richeldi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies
A. du Bois et al.
ANNALS OF ONCOLOGY (2010)
Phase I Study of the Angiogenesis Inhibitor BIBF 1120 in Patients with Advanced Solid Tumors
Klaus Mross et al.
CLINICAL CANCER RESEARCH (2010)
Phase I Open-Label Study of Continuous Treatment with BIBF 1120, a Triple Angiokinase Inhibitor, and Pemetrexed in Pretreated Non-Small Cell Lung Cancer Patients
Peter M. Ellis et al.
CLINICAL CANCER RESEARCH (2010)
BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy
Frank Hilberg et al.
CANCER RESEARCH (2008)
Share Paper
